Hematopoietic stem cell transplantation in multiple sclerosis

References

• Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N. Engl. J. Med. 354(9), 942–955 (2006).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338(5), 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179(3), 973–984 (1994).
   PubMed Web of Science ®Google Scholar
• Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247(4943), 718–721 (1990).
   PubMed Web of Science ®Google Scholar
• Wucherpfennig KW, Hafler DA. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann. NY Acad. Sci. 756, 241–258 (1995).
   PubMed Web of Science ®Google Scholar
• Venken K, Hellings N, Hensen K, Rummens JL, Stinissen P. Memory CD4+CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens. J. Neuroimmunol. 226(1–2), 185–191 (2010).
   PubMedGoogle Scholar
• Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol. Rev. 223, 87–113 (2008).
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485–517 (2009).
   PubMed Web of Science ®Google Scholar
• Kebir H, Kreymborg K, Ifergan I et al. Human Th17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13(10), 1173–1175 (2007).
   PubMed Web of Science ®Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132(Pt 5), 1175–1189 (2009).
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130(Pt 4), 1089–1104 (2007).
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Popescu BF, Bunyan RF et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365(23), 2188–2197 (2011).
   PubMed Web of Science ®Google Scholar
• Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 290(5497), 1779–1782 (2000).
   PubMed Web of Science ®Google Scholar
• Cogle CR, Yachnis AT, Laywell ED et al. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet 363(9419), 1432–1437 (2004).
   PubMed Web of Science ®Google Scholar
• Cabanes C, Bonilla S, Tabares L, Martínez S. Neuroprotective effect of adult hematopoietic stem cells in a mouse model of motoneuron degeneration. Neurobiol. Dis. 26(2), 408–418 (2007).
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp. Hematol. 28(7), 853–857 (2000).
   PubMed Web of Science ®Google Scholar
• Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult. Scler. 17(2), 204–213 (2011).
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Inaba M, Miyashima S, Ogawa R, Ikehara S. A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood 91(12), 4616–4623 (1998).
   PubMed Web of Science ®Google Scholar
• Ikehara S, Ohtsuki H, Good RA et al. Prevention of Type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation. Proc. Natl Acad. Sci. USA 82(22), 7743–7747 (1985).
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN. Role of the thymus in murine lupus and cellular transfer of the disease. Arthritis Rheum. 25(7), 726–733 (1982).
   PubMedGoogle Scholar
• Ikehara S, Good RA, Nakamura T et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc. Natl Acad. Sci. USA 82(8), 2483–2487 (1985).
   PubMed Web of Science ®Google Scholar
• Nishioka N, Toki J, Cherry et al. Repair mechanism of lupus nephritis in (NZB × NZW)F1 mice by allogeneic bone marrow transplantation. Immunobiology 192(5), 279–296 (1995).
   PubMed Web of Science ®Google Scholar
• Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O. Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult. Scler. 5(1), 17–21 (1999).
   PubMed Web of Science ®Google Scholar
• Karussis DM, Slavin S, Ben-Nun A et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J. Neuroimmunol. 39(3), 201–210 (1992).
   PubMedGoogle Scholar
• Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J. Immunol. 148(6), 1693–1698 (1992).
   PubMed Web of Science ®Google Scholar
• Karussis DM, Vourka-Karussis U, Lehmann D, Abramsky O, Ben-Nun A, Slavin S. Immunomodulation of autommunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT). Clin. Exp. Immunol. 100(1), 111–117 (1995).
   PubMed Web of Science ®Google Scholar
• Verda L, Kim DA, Ikehara S et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 26(2), 381–386 (2008).
   PubMed Web of Science ®Google Scholar
• Kojima R, Kami M, Kim SW et al. Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 32(4), 439–442 (2003).
   PubMed Web of Science ®Google Scholar
• Loh Y, Oyama Y, Statkute L et al. Non-myeloablative allogeneic hematopoietic stem cell transplantation for severe systemic sclerosis: graft-versus-autoimmunity without graft-versus-host disease? Bone Marrow Transplant. 39(7), 435–437 (2007).
   PubMed Web of Science ®Google Scholar
• Slavin S, Aker M, Shapira MY, Resnick I, Bitan M, Or R. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Clin. Transpl. 275–282 (2003).
   PubMedGoogle Scholar
• Snowden JA, Kearney P, Kearney A et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum. 41(3), 453–459 (1998).
   PubMed Web of Science ®Google Scholar
• Yin JA, Jowitt SN. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant. 9(1), 31–33 (1992).
   PubMed Web of Science ®Google Scholar
• Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J. Rheumatol. 20(1), 137–140 (1993).
   PubMed Web of Science ®Google Scholar
• Karussis DM, Vourka-Karussis U, Lehmann D et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J. Clin. Invest. 92(2), 765–772 (1993).
   PubMedGoogle Scholar
• van Gelder M, Kinwel-Bohré EP, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant. 11(3), 233–241 (1993).
   PubMed Web of Science ®Google Scholar
• van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant. 16(3), 343–351 (1995).
   PubMed Web of Science ®Google Scholar
• van Bekkum DW, Bohre EP, Houben PF, Knaan-Shanzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc. Natl Acad. Sci. USA 86(24), 10090–10094 (1989).
   PubMed Web of Science ®Google Scholar
• Farge D, Labopin M, Tyndall A et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95(2), 284–292 (2010).
   PubMed Web of Science ®Google Scholar
• Karussis D, Vaknin-Dembinsky A. Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting. Expert Rev. Clin. Immunol. 6(3), 347–352 (2010).
   PubMedGoogle Scholar
• Saccardi R, Kozak T, Bocelli-Tyndall C et al.; Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult. Scler. 12(6), 814–823 (2006).
   PubMed Web of Science ®Google Scholar
• Saccardi R, Mancardi GL, Solari A et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105(6), 2601–2607 (2005).
   PubMed Web of Science ®Google Scholar
• Mondria T, Lamers CH, te Boekhorst PA, Gratama JW, Hintzen RQ. Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 79(9), 1013–1015 (2008).
   PubMedGoogle Scholar
• Fassas A, Anagnostopoulos A, Kazis A et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 20(8), 631–638 (1997).
   PubMed Web of Science ®Google Scholar
• Fassas A, Kimiskidis VK, Sakellari I et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76(12), 1066–1070 (2011).
   PubMedGoogle Scholar
• Burt RK, Cohen BA, Russell E et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102(7), 2373–2378 (2003).
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Cohen B et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a Phase I/II study. Lancet Neurol. 8(3), 244–253 (2009).
   PubMed Web of Science ®Google Scholar
• Shevchenko YL, Novik AA, Kuznetsov AN et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp. Hematol. 36(8), 922–928 (2008).
   PubMed Web of Science ®Google Scholar
• Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin. Transplant. 20(4), 485–489 (2006).
   PubMedGoogle Scholar
• Krasulová E, Trneny M, Kozák T et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult. Scler. 16(6), 685–693 (2010).
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Sormani MP, Di Gioia M et al.; Italian BMT Study Group. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multicentre experience. Mult. Scler. 18(6), 835–842 (2012).
   PubMed Web of Science ®Google Scholar
• Metz I, Lucchinetti CF, Openshaw H et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130(Pt 5), 1254–1262 (2007).
   PubMed Web of Science ®Google Scholar
• Lu JQ, Joseph JT, Nash RA et al. Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. Arch. Neurol. 67(6), 716–722 (2010).
   PubMedGoogle Scholar
• Lu JQ, Storek J, Metz L et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch. Neurol. 66(1), 116–120 (2009).
   PubMedGoogle Scholar
• Saccardi R, Freedman MS, Sormani MP et al.; European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; HSCT in MS International Study Group. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult. Scler. 18(6), 825–834 (2012).
   PubMed Web of Science ®Google Scholar
• Muraro PA, Douek DC, Packer A et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 201(5), 805–816 (2005).
   PubMed Web of Science ®Google Scholar
• Samijn JP, te Boekhorst PA, Mondria T et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 77(1), 46–50 (2006).
   PubMed Web of Science ®Google Scholar
• Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL; Canadian MS BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66(12), 1935–1937 (2006).
   PubMed Web of Science ®Google Scholar
• Rocca MA, Mondria T, Valsasina P et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR. Am. J. Neuroradiol. 28(9), 1659–1661 (2007).
   PubMed Web of Science ®Google Scholar
• Roccatagliata L, Rocca M, Valsasina P et al.; Italian GITMO-NEURO Intergroup on Autologous Stem Cell Transplantation. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult. Scler. 13(8), 1068–1070 (2007).
   PubMedGoogle Scholar
• Daikeler T, Hügle T, Farge D et al.; Working Party Autoimmune Diseases of the EBMT. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant. 44(1), 27–33 (2009).
   PubMed Web of Science ®Google Scholar
• Griffith LM, Pavletic SZ, Tyndall A et al.; Workshop participants. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol. Blood Marrow Transplant. 11(11), 862–870 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Kamezaki K, Takeishi S et al. Encephalomyelitis mimicking multiple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Intern. Med. 48(16), 1453–1456 (2009).
   PubMedGoogle Scholar
• Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjögren syndrome and scleroderma. Br. J. Haematol. 66(1), 45–47 (1987).
   PubMedGoogle Scholar
• Bacigalupo A, Ballen K, Rizzo D et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. 15(12), 1628–1633 (2009).
   PubMed Web of Science ®Google Scholar
• Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 85(3), 304–313 (2000).
   PubMed Web of Science ®Google Scholar
• Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 25(4), 345–350 (2000).
   PubMed Web of Science ®Google Scholar
• Kozák T, Havrdová E, Pit’ha J et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant. Proc. 33(3), 2179–2181 (2001).
   PubMedGoogle Scholar
• Fassas A. Autologous stem cell transplants in treatment of multiple sclerosis: where we stand and future prospects. Int. J. Hematol. 76(Suppl. 1), 223–225 (2002).
   PubMedGoogle Scholar
• Nash RA, Bowen JD, McSweeney PA et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102(7), 2364–2372 (2003).
   PubMed Web of Science ®Google Scholar
• Carreras E, Saiz A, Marín P et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 88(3), 306–314 (2003).
   PubMed Web of Science ®Google Scholar
• Inglese M, Mancardi GL, Pagani E et al.; Italian GITMO-NEURO Group on Autologous Hematopoietic Stem Cell Transplantation. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J. Neurol. Neurosurg. Psychiatr. 75(4), 643–644 (2004).
   PubMed Web of Science ®Google Scholar
• Xu J, Ji BX, Su L, Dong HQ, Sun XJ, Liu CY. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin. Med. J. 119(22), 1851–1855 (2006).
   PubMedGoogle Scholar
• Freedman MS Atkins HL, Arnold DL, Bar-Or A. Immune ablation and autologous stem cell transplantation for aggressive multiple sclerosis: interim 5-year report. Mult. Scler. 13, Abstract Supp.22 (2007).
   PubMedGoogle Scholar
• Saiz A, Blanco Y, Berenguer J et al. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis]. Neurologia. 23(7), 405–407 (2008).
   PubMedGoogle Scholar
• Openshaw H, Lund BT, Kashyap A et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol. Blood Marrow Transplant. 6(5A), 563–575 (2000).
   PubMed Web of Science ®Google Scholar
• Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult. Scler. 15(2), 229–237 (2009).
   PubMed Web of Science ®Google Scholar
• Hamerschlak N, Rodrigues M, Moraes DA et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant. 45(2), 239–248 (2010).
   PubMed Web of Science ®Google Scholar
• Xu J, Ji BX, Su L et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann. Hematol. 90(3), 343–348 (2011).
   PubMed Web of Science ®Google Scholar
• Bowen JD, Kraft GH, Wundes A et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 47(7), 946–951 (2012).
   PubMed Web of Science ®Google Scholar